The diarylquinoline TMC207 for multidrug-resistant tuberculosis
about
A brief history of the antibiotic era: lessons learned and challenges for the futureCulture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South AfricaTMC207 for treatment of people with pulmonary tuberculosisFluoroquinolones for treating tuberculosis (presumed drug-sensitive)TMC207: the first compound of a new class of potent anti-tuberculosis drugsNew Antituberculosis Drugs: From Clinical Trial to Programmatic UseNew agents for the treatment of drug-resistant Mycobacterium tuberculosisCarbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic ReviewManagement of multidrug-resistant TB: novel treatments and their expansion to low resource settingsEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Medical Management of Drug-Resistant TuberculosisBedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Antituberculosis therapy for 2012 and beyondExtensively drug-resistant tuberculosis: epidemiology and managementWho will develop new antibacterial agents?Role of microparticles in dengue virus infection and its impact on medical intervention strategiesBedaquiline: a review of human pharmacokinetics and drug-drug interactionsRising to the challenge: new therapies for tuberculosisTriazaspirodimethoxybenzoyls as Selective Inhibitors of Mycobacterial Lipoamide Dehydrogenase,Variations of Subunit of the Mycobacterium tuberculosis F1Fo ATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207Piperidinols That Show Anti-Tubercular Activity as Inhibitors of Arylamine N-Acetyltransferase: An Essential Enzyme for Mycobacterial Survival Inside MacrophagesTowards a new combination therapy for tuberculosis with next generation benzothiazinonesUse of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerationsRecent Developments and Future Opportunities in the Treatment of Tuberculosis in ChildrenHigh morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomenaHigh content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitorsThe antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosisProbing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthaseSterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosisRapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamideAggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityDiagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.Global financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatmentSuccinate dehydrogenase is the regulator of respiration in Mycobacterium tuberculosisBibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015)New anti-tuberculosis drugs and regimens: 2015 updateEfflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosisPipeline of drugs for related diseases: tuberculosisEstablishing Virulence Associated Polyphosphate Kinase 2 as a drug target for Mycobacterium tuberculosisIdentification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars
P2860
Q21131155-C6E1A4FC-D36D-41FE-9B0A-58A7D8B11A19Q21562122-F9083FA2-8983-47EE-90B7-22178D68BD08Q24199155-EE2FE6CB-F584-4351-ACD3-7300709833BCQ24202081-6E4C83D0-7AFF-4AB0-84CD-EE16862FA910Q24632091-6C25E639-2B05-473E-A8B7-4DA0B860A7E1Q26741138-84AE77FA-36B5-473F-948E-EB5EE2B3D9BCQ26751463-64EAFE58-34A9-4D89-A48C-8056B9A79897Q26764847-F9BF80F3-90BD-45C2-88E6-0333848A292FQ26765394-FC30AD34-5321-4B01-AD54-BC6705C90E9CQ26771997-0098A16D-E22C-482F-B82A-9288518EADC8Q26801601-AFE2DC1A-C45C-4387-A602-51EFE61BB609Q26824413-A0085232-71BA-4772-AFBB-D371F8FE849FQ26829101-7127B1BF-486E-4DA6-8D12-C8DEB2C36B80Q26830094-89FE0D84-A1B5-4382-A550-C8C4E3A71920Q26851875-B067EA64-A3AF-4D50-A8F8-940F462F1819Q26860307-C99CD9C6-5074-4D5B-8A0C-9BC38D6ABDC9Q26864991-AAAD2628-5417-4FCA-94E5-42450AC84AF0Q27011672-03EBA613-3634-4CA8-835B-F5C9380E65EBQ27658975-CE88ACB6-A4C6-41DB-93CA-B070EBF44A8BQ27674675-0ADC6D60-97F5-46D5-ACCA-F95D7B7C455FQ27675714-13352467-3ABB-4015-AC85-9DC29CC506BDQ27681604-2B9B6ED2-BD48-455B-B8A9-7EEFB87FA663Q28072205-32D8B915-C34E-49CF-8F7A-76068AF94799Q28085210-56731EF7-CD6A-4D12-B292-F5BD879F71A9Q28391941-EB04FC5C-977F-4536-A329-1BBB350C01EAQ28471626-AEE72BD3-570C-4460-BC03-752EF630875CQ28475461-56CB4CB6-50FB-4C95-9F6B-A8024C1BFE89Q28476612-989AEFA3-F51F-469F-BA01-BC64DDD905D8Q28477317-AD5839D0-B3EB-4243-9F3F-B7E0F43DE317Q28478966-2E9A1F2C-079B-47D9-8678-3D30E8BF58D3Q28487938-63592579-42EE-4180-8C5C-8DCD346DF2EEQ28487970-001C29AD-36F1-4AC1-B886-B6C9854C9BC2Q28543392-550BCAE2-4A43-4950-8715-013EC432427CQ28545101-4DE3D233-398D-4DD1-9808-EB4E25D7828BQ28555235-D6E04DD8-8F58-4CE2-9380-4F4785EADFC0Q28596775-8822C611-4011-45C9-AA56-1523CA90643DQ28659633-084CFEEC-94E3-45C1-B16C-318EB98A8B1EQ28818217-E1782D67-5DF8-430E-9C41-E39DB4182C18Q28828317-902B8F3D-114A-41C0-AABB-0ACA886AF30DQ28833704-F07AC9E4-0E99-40AF-8AA4-9DC977F672DC
P2860
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@ast
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@en
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@nl
type
label
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@ast
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@en
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@nl
prefLabel
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@ast
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@en
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@nl
P2093
P3181
P356
P1476
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
@en
P2093
Amour Venter
Andreas H Diacon
Christoffel Pistorius
David F Mc Neeley
Jenny Allen
Johan Verbeeck
Juan Carlos Palomino
Karel de Beule
Koen Andries
Liesl Page-Shipp
P304
P3181
P356
10.1056/NEJMOA0808427
P407
P577
2009-06-01T00:00:00Z